Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease

British Journal of Haematology

Volumn 118, Issue 1, 2002, Pages 195-201

  Reynolds, Gary M ^a   Billingham, Lucinda J ^a   Gray, Laura J ^a   Flavell, Joanne R ^a   Najafipour, Sohrab ^a   Crocker, John ^b   Nelson, Paul ^c   Young, Lawrence S ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

'B' symptoms; Hodgkin's disease; Immunohistochemistry; Interleukin 6; Remission

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 6; PARAFFIN; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REDUCTION; REED STERNBERG CELL; REMISSION; SERUM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; REED-STERNBERG CELLS; REGRESSION ANALYSIS; REMISSION INDUCTION;

EID: 0036069776     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03575.x     Document Type: Article

References (31)

1. Interleukin-6 in biology and medicine
2. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
3. Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection
4. The biological effects of interleukin 6
5. Biological effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
6. Interleukin-6-associated laboratory parameters and immunohistochemistry in symptomatic stage A and B nodular sclerosing Hodgkin's disease in children
7. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
8. ChIVPP/PABIOE and radiotherapy in advanced Hodgkin's disease
9. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors
10. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production
11. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms
12. Lymphotoxin, tumour necrosis factor and interleukin 6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases
13. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease
14. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial
15. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation/Central Lymphoma Group randomised controlled trial
16. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells
17. Interleukin-6 prevents dexamethasone-induced myeloma cell death
18. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus
19. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease
20. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
21. Production of multiple cytokines by Hodgkin's disease derived cell lines
22. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
23. Hodgkin's disease: A disorder of dysregulated cellular cross talk
24. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity
25. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease
26. Interleukin-6 immunoreactivity in human tumors
27. Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors
28. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis
29. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB
30. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders
31. Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL-6 antibodies indicates the existence of a positive feed-back loop